To investigate the role of intrinsic PD-1 signaling in neoplastic cells, the effect of human anti-PD-1, nivolumab, was evaluated in combination with the newest and most powerful CXCR4 antagonist Pep R54 [20] in a xenograft model of human melanoma. This evidence concerns the gene CXCR4 and melanoma.